Global Choroidal Neovascularization Top Major Players 2025, Forecast To 2034
26 Mar, 2025
How Has the Choroidal Neovascularization Market Size Evolved in Recent Years?
The choroidal neovascularization market has seen considerable growth due to a variety of factors.
• The market for choroidal neovascularization has been witnessing robust growth in recent years. The market is projected to expand from $3.37 billion in 2024 to $3.61 billion by 2025, reflecting a compound annual growth rate (CAGR) of 8.1%.
The substantial growth during the historic period can be traced back to factors such as the climbing rates of diseases linked to a sedentary lifestyle, an increase in age-related macular degeneration cases, an upsurge in retinal illnesses, the growing population of the elderly, increasing expenses in eye care, and broadened education and screening initiatives regarding eye health.
What Are The Predictions for The Choroidal Neovascularization Template Market?
The choroidal neovascularization market is expected to maintain its strong growth trajectory in upcoming years.
• The market for choroidal neovascularization is anticipated to witness a robust rise in the coming years, foreseeing a growth to $5.64 billion by 2029, with a compound annual growth rate (CAGR) of 7.7%.
This predicted growth in the forecast period is credited to rising patient awareness, increasing use of optical coherence tomography angiography, increasing demand for minimally invasive procedures, favorable reimbursement policies, and an aging population. Key trends for the forecast period comprise the introduction of intravitreal anti-vascular endothelial (VEGF) therapies, novel gene treatments, gene therapy methods, telemedicine uptake, the formulation of combination therapies, and individualized treatment protocols.
What Main Forces Are Fueling Expansion In The Choroidal Neovascularization Market?
Anticipated advances in the choroidal neovascularization (CNV) market are likely to be fuelled by an upsurge of age-related macular degeneration (AMD), an optical ailment that gradually impairs the macula, mostly in more elderly adults, resulting in a loss of central vision. Changes in lifestyle, increased longevity, genetic traits, environmental risks, and an aging population factor into the growing incidence of age-related macular degeneration (AMD). Choroidal neovascularization (CNV) plays a crucial role in age-related macular degeneration (AMD), ultimately leading to the onset of wet AMD, where irregular blood vessels grow beneath the retina causing a decline in vision. This necessitates advanced remedies like anti-VEGF treatment to control choroidal neovascularization (CNV) and hinder the development of age-related macular degeneration (AMD), thereby protecting central vision in those affected. For instance, data from the National Institutes of Health, a US government agency, predicts that by 2040, there may be 300 million cases of age-related macular degeneration (AMD) and by 2050, the disease could impact 5.4 million Americans. Consequently, the escalating frequency of age-related macular degeneration propels the expansion of the choroidal neovascularization market.
What Are The Core Segments Of The Global Choroidal Neovascularization Market?
The choroidal neovascularization market covered in this report is segmented –
1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium
2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications
3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral
4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers
Subsegments:
1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium
2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy
3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT
4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF
5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen
6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections
7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen
8) By Pegaptanib Sodium: Monotherapy, Combination Therapy
Which Emerging Trends Are Reshaping The Choroidal Neovascularization Market Size?
Major firms in the choroidal neovascularization sector are sharpening their focus on the creation of innovative treatment methods including photodynamic therapy (PDT). This approach equips eye care professionals with the precise and effective tools they need to improve patient results and streamline treatment administration. PDT is a clinical procedure that involves the use of a photosensitizing agent, which, when activated by light, targets and eliminates abnormal or malignant cells. Notably, in February 2023, Canada's Bausch & Lomb and Finland's Modulight revealed the FDA's approval of the ML6710i photodynamic laser. This laser is approved to be used in conjunction with Bausch + Lomb’s therapy named VISUDYNE, an innovative treatment developed to combat choroidal neovascularization that is a result of age-related macular degeneration (AMD). This sophisticated, portable ophthalmic laser affords a specific solution to the treatment of irregular blood vessels in the eye, hence aiding in halting further advancement of the disease and maintaining sight.
Who Are the Key Players In The Choroidal Neovascularization Market?
Major companies operating in the choroidal neovascularization market are:
• Pfizer Inc.
• Roche Holding AG
• AbbVie Inc.
• Bayer Aktiengesellschaft
• Novartis AG
• Teva Pharmaceutical Industries Limited
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Biogen Inc.
• Chugai Pharmaceutical Co. Ltd.
• Alcon Inc.
• Genentech Inc.
• Bausch + Lomb Incorporated
• Samsung Bioepis Co. Ltd.
• Santen Pharmaceutical Co. Ltd.
• Apellis Pharmaceuticals Inc.
• Kodiak Sciences Inc.
• Xbrane Biopharma AB
• Allergan Inc.
• Adverum Biotechnologies Inc.
• Clearside Biomedical Inc.
• Sylentis S.A.
What Are The Regional Insights Into The Choroidal Neovascularization Market?
North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.